CalciMedica shares surge 17.65% after-hours after reporting no drug-related toxicity in KOURAGE trial and advancing acute pancreatitis program.

CalciMedica surged 17.65% in after-hours trading following its release of 2025 financial results and clinical updates, which highlighted no drug-related toxicity in its Phase 2 KOURAGE trial for acute kidney injury (AKI) and outlined plans to finalize a pivotal program for acute pancreatitis (AP) in H1 2026. The company also disclosed preclinical data for CM5480 in pulmonary arterial hypertension (PAH), with an IND submission expected in 2027. These developments addressed prior safety concerns, reinforced the pipeline’s potential, and aligned with the CEO’s optimistic outlook, including constructive FDA engagement for AP. While a $125 million mixed shelf filing (Reasons 2 and 3) and financial constraints (Reason 4) raised dilution risks, the immediate catalyst was the positive clinical and strategic updates, which drove investor confidence in the company’s near-term pipeline progress and regulatory pathway.